Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
Open Access
- 3 August 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Computational Biology
- Vol. 16 (8), e1008041
- https://doi.org/10.1371/journal.pcbi.1008041
Abstract
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful in vitro and in vivo, HAPs are yet to achieve successful results in clinical settings. It has been hypothesised that this lack of clinical success can, in part, be explained by the insufficiently stringent clinical screening selection of determining which tumours are suitable for HAP treatments. Taking a mathematical modelling approach, we investigate how tumour properties and HAP-radiation scheduling influence treatment outcomes in simulated tumours. The following key results are demonstrated in silico: (i) HAP and ionising radiation (IR) monotherapies may attack tumours in dissimilar, and complementary, ways. (ii) HAP-IR scheduling may impact treatment efficacy. (iii) HAPs may function as IR treatment intensifiers. (iv) The spatio-temporal intra-tumoural oxygen landscape may impact HAP efficacy. Our in silico framework is based on an on-lattice, hybrid, multiscale cellular automaton spanning three spatial dimensions. The mathematical model for tumour spheroid growth is parameterised by multicellular tumour spheroid (MCTS) data. When cancer patients present with solid tumours, the tumours often contain regions that are oxygen-deprived or, in other words, hypoxic. Hypoxic tumour regions are more resistant to conventional anti-cancer therapies, such as chemotherapy and radiotherapy, and therefore tumour hypoxia may complicate treatments. Hypoxia-activated prodrugs constitute a conceptually elegant approach to not only overcome, but better yet, exploit tumour hypoxia. Hypoxia-activated prodrugs are drugs that act as Trojan horses, they are theoretically harmless vehicles that are converted into warheads when they reach their targets: hypoxic tumour regions. Despite being conceptually clever and successful in experimental settings, hypoxia-activated prodrugs are yet to achieve successful results in clinical trials. It has been hypothesised that this lack of clinical success can, in part, be explained by an insufficiently stringent clinical screening selection of determining which tumours are suitable for hypoxia-activated prodrug treatments. In this article, we investigate how simulated tumours with different oxygen landscapes respond to anti-cancer treatments that include hypoxia-activated prodrugs, either alone or in combination with radiotherapy. Our simulation framework is based on a mathematical model that describes how individual cancer cells in a tumour divide and respond to treatments. We demonstrate that the efficacy of hypoxia-activated prodrugs depends on both the treatment scheduling and the oxygen landscapes of the simulated tumours.This publication has 50 references indexed in Scilit:
- In Silico Analysis of Cell Cycle Synchronisation Effects in Radiotherapy of Tumour SpheroidsPLoS Computational Biology, 2013
- The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104Frontiers in Oncology, 2013
- Modeling the Spatial Distribution of Chronic Tumor Hypoxia: Implications for Experimental and Clinical StudiesComputational and Mathematical Methods in Medicine, 2012
- Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in ratsXenobiotica, 2011
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid MalignanciesClinical Cancer Research, 2011
- Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugBlood, 2010
- The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of MitoxantroneCancer Research, 2009
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer DrugsJournal of Medicinal Chemistry, 2008
- A mathematical model of the effects of hypoxia on the cell-cycle of normal and cancer cellsJournal of Theoretical Biology, 2004
- Regulation of the Eukaryotic Cell Cycle: Molecular Antagonism, Hysteresis, and Irreversible TransitionsJournal of Theoretical Biology, 2001